Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-17-005719
Filing Date
2017-01-26
Accepted
2017-01-26 16:25:43
Documents
1
Period of Report
2017-01-26

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 4400
  Complete submission text file 0001209191-17-005719.txt   6551
Mailing Address 86 MORRIS AVENUE SUMMIT NJ 07901
Business Address 86 MORRIS AVENUE SUMMIT NJ 07901 (908)673-9000
CELGENE CORP /DE/ (Reporting) CIK: 0000816284 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-37998 | Film No.: 17550034
SIC: 2834 Pharmaceutical Preparations

Mailing Address 1030 MASSACHUSETTS AVE. CAMBRIDGE MA 02138
Business Address 1030 MASSACHUSETTS AVE. CAMBRIDGE MA 02138 857-259-3840
Jounce Therapeutics, Inc. (Issuer) CIK: 0001640455 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address AON HOUSE 30 WOODBOURNE AVENUE PEMBROKE D0 HM 08
Business Address AON HOUSE 30 WOODBOURNE AVENUE PEMBROKE D0 HM 08 4412964803
Celgene Switzerland LLC (Reporting) CIK: 0001661486 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-37998 | Film No.: 17550035